

# A Kinetic Binding Study to Evaluate the Pharmacological Profile of a Specific Leukotriene C<sub>4</sub> Binding Site Not Coupled to Contraction in Human Lung Parenchyma

SAULA RAVASI, VALÉRIE CAPRA, MAURIZIO MEZZETTI, SIMONETTA NICOSIA, and G. ENRICO ROVATI

Laboratory of Molecular Pharmacology, Institute of Pharmacological Sciences, University of Milan, Milan, Italy (S.R., V.C., S.N., G.E.R.); and San Paolo Hospital, Department of Clinical Surgery, Milan, Italy (M.M.)

Received September 17, 1999; accepted February 17, 2000

This paper is available online at <http://www.molpharm.org>

## ABSTRACT

We report the identification of a novel pharmacological profile for the leukotriene (LT)C<sub>4</sub> binding site we previously identified in human lung parenchyma (HLP). We used a series of classic cysteinyl-LT (CysLT)<sub>1</sub> receptor antagonists belonging to different chemical classes and the dual CysLT<sub>1</sub>-CysLT<sub>2</sub> antagonist BAY u9773 for both binding and functional studies. Because the presence of (S)-decyl-glutathione interfered with cysteinyl-LT binding, with a kinetic protocol we avoided the use of this compound. By means of heterologous dissociation time courses, we demonstrated that zafirlukast, iralukast, and BAY u9773 selectively competed only for <sup>3</sup>H-LTD<sub>4</sub> binding sites, whereas pobilukast, pranlukast, and CGP 57698 dissociated both <sup>3</sup>H-LTC<sub>4</sub> and <sup>3</sup>H-LTD<sub>4</sub> from their binding sites. Thus, with binding studies, we have been able to identify a pharmacolog-

ical profile for LTC<sub>4</sub> distinct from that of LTD<sub>4</sub> receptor (CysLT<sub>1</sub>) in HLP. On the contrary, in functional studies, all of the classic antagonists tested were able to revert both LTC<sub>4</sub>- and LTD<sub>4</sub>-induced contractions of isolated HLP strips. Thus, LTD<sub>4</sub> and LTC<sub>4</sub> contract isolated HLP strips through the same CysLT<sub>1</sub> receptor. The results of kinetic binding studies, coupled to a sophisticated data analysis, confirm our hypothesis that HLP membranes contain two cysteinyl-LT high-affinity binding sites with different pharmacological profiles. In functional studies, however, LTD<sub>4</sub>- and LTC<sub>4</sub>-induced contractions are mediated by the same CysLT<sub>1</sub> receptor. In conclusion, the specific LTC<sub>4</sub> high-affinity binding site cannot be classified as one of the officially recognized CysLT receptors, and it is not implicated in LTC<sub>4</sub>-induced HLP strip contractions.

It has long been accepted that cysteine-containing leukotrienes (cysteinyl-LTs) LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>, play an important role in asthma, participating in both the bronchoconstriction and the chronic inflammatory component of the disease. CysLTs originate from the oxidative metabolism of arachidonic acid through a key enzyme, 5-lipoxygenase, in a number of inflammatory cells, including eosinophils, basophils, mast cells, and macrophages (Drazen and Austen, 1987; Hay et al., 1995).

CysLTs exert their actions through the activation of specific receptors, the first of which was recently cloned (Lynch et al., 1999). However, in human airways, all the interest has been focused on LTD<sub>4</sub>, whereas LTC<sub>4</sub> has been considered either only a precursor or an equipotent/equieffective agonist (Buckner et al., 1986) and LTE<sub>4</sub> has been considered as a metabolite with partial agonist activity (Saussy et al., 1989). Moreover, it is generally believed that in human airways, LTC<sub>4</sub> acts on the same receptor as LTD<sub>4</sub>, either CysLT<sub>1</sub> in bronchi (Buckner et al., 1986,

1990; Hay et al., 1987) or CysLT<sub>2</sub> in human pulmonary veins (Labat et al., 1992).

We recently pointed out that in human lung parenchyma (HLP) membranes, LTC<sub>4</sub> possesses a specific high-affinity binding site with characteristics distinct from those of LTD<sub>4</sub> (Capra et al., 1998). In particular, in this tissue, two of the classic CysLT<sub>1</sub> antagonists [i.e., pobilukast and ICI 198,615 (from which zafirlukast has been derived)] behaved differently against <sup>3</sup>H-LTC<sub>4</sub> and <sup>3</sup>H-LTD<sub>4</sub> at equilibrium, thus suggesting the idea that two different receptors might exist. However, all of the experiments have been performed in the presence of (S)-decyl-glutathione [(S)-decyl-GSH], a compound devoid of either agonist or antagonist activities, which, as it will be demonstrated, interferes with antagonist binding and prevents a complete pharmacological characterization. On the basis of these results, we avoided the use of (S)-decyl-GSH and characterized these two distinct binding sites with a series of antagonists (Fig. 1) in both kinetic binding studies in HLP membranes and contraction of HLP strips.

**ABBREVIATIONS:** Cysteinyl-LT, cysteine-containing leukotrienes; LT, leukotriene; (S)-decyl-GSH, (S)-decyl-glutathione; PG, prostaglandin; HLP, human lung parenchyma; Gpp(NH)p, guanosine-5'-( $\beta$ ,  $\gamma$ -imido)triphosphate.

## Experimental Procedures

**Materials.** <sup>3</sup>H-LTC<sub>4</sub> (164–173 Ci/mmol) and <sup>3</sup>H-LTD<sub>4</sub> (164–173 Ci/mmol) were purchased from DuPont NEN (Boston, MA). LTC<sub>4</sub> and prostaglandin (PG)F<sub>2α</sub> were purchased from Cayman Chemical Co. (Ann Arbor, MI). Pobilukast (SKF 104353) was kindly provided by SmithKline and Beecham Laboratories (King of Prussia, PA). LTD<sub>4</sub>, zafirlukast (ICI 204,219), pranlukast (ONO 1078), iralukast (CGP 45715A), and CGP 57698 were a generous gift of Dr. A. von Sprecher (Novartis, Basel, Switzerland). Guanosine-5'-(β,γ-imido) triphosphate [Gpp(NH)p], (S)-decyl-GSH, cysteine, glycine, boric acid, serine, indomethacin, Tyrode's salts, and HEPES were purchased from Sigma Chemical Co. (St Louis, MO). Filtercount was from Packard Instruments Co. (Meriden, CT). All the reagents used in HPLC analysis were of analytical grade and purchased from Carlo Erba (Milan, Italy), as were GF/C Whatman Fiberglass filters.

**Preparation of HLP Membranes.** Crude membranes were prepared from macroscopically normal specimens removed at thoracotomy for lung cancer as previously described (Rovati et al., 1985). Briefly, specimens were minced, homogenized at 4° in 10 mM HEPES buffer, pH 7.4 (1:24, w/v), and centrifuged at 770g for 10 min, and the supernatant was centrifuged at 27,000g for 20 min. The pellet was resuspended, centrifuged under the same condition, and finally resuspended in 5% of the homogenization volume. Membrane aliquots were frozen at –80° and stored for no longer than 3 months. Protein content was determined according to the Bradford dye-binding protein assay (Pierce Chemical Co., Rockford, IL). Before use,

serine-borate complex (40 mM final concentration in the assay, prepared as an equimolar solution of serine and boric acid), cysteine (10 mM), and glycine (10 mM) were added to the membrane suspension to avoid cysteinyl-LT metabolism.

**Reverse Phase HPLC.** Labeled and unlabeled leukotriene purity was always assessed by reverse phase HPLC. Only leukotrienes with a purity grade greater than or equal to 90% were used. The Beckman HPLC system was equipped with a 110B Solvent Delivery Module, an ODS Ultrasphere C18 column, and a programmable detector module 166 set at 280 nm. Both labeled and unlabeled leukotrienes were eluted isocratically with a filtered and degassed mixture of CH<sub>3</sub>OH:H<sub>2</sub>O:CH<sub>3</sub>COOH (65:35:0.02 v/v/v), adjusted at pH 5.8 with NH<sub>4</sub>OH, at a flow rate of 1 ml/min. To check the purity of tritiated leukotrienes, fractions were collected every 30 s, and the radioactivity profile assessed by liquid scintillation counting (Ultima Gold; Packard).

**Binding Studies.** Equilibrium binding studies were performed at 25°C for 30 min with 0.5 nM <sup>3</sup>H-LTD<sub>4</sub> or <sup>3</sup>H-LTC<sub>4</sub> and unlabeled homologous or heterologous ligands at the indicated concentrations, in the absence and presence of 10 μM (S)-decyl-GSH.

Association time courses were performed at 25°C with 0.5 nM <sup>3</sup>H-LTC<sub>4</sub> or <sup>3</sup>H-LTD<sub>4</sub> to label the high-affinity binding sites and with a total ligand concentration of 0.1 μM (mixture of 1 nM labeled ligand plus 0.1 μM unlabeled homologous ligand) to also label the low-affinity sites. The experiments were conducted for 30 or 60 min for <sup>3</sup>H-LTD<sub>4</sub> and <sup>3</sup>H-LTC<sub>4</sub>, respectively. Dissociation was induced by




Fig. 1. Chemical structures of LTC<sub>4</sub>, LTD<sub>4</sub>, and receptor antagonists.


the addition of 1  $\mu\text{M}$  unlabeled leukotriene (homologous dissociation) or 10  $\mu\text{M}$  unlabeled antagonist (heterologous dissociation). Gp-p(NH)p was used at a concentration of 30  $\mu\text{M}$  where indicated.

In both equilibrium and kinetic studies, HLP membranes (0.25 mg/sample), 10 mM HEPES-KOH, pH 7.4, and 1 mM  $\text{CaCl}_2$  were added to the incubation mixture to achieve a final volume of 250  $\mu\text{l}$ . Unbound ligand was separated by rapid vacuum filtration (Brandel Cell Harvester) onto glass-fiber GF/C filters (Whatman) soaked in 2.5% polyvinyl alcohol, and the filters were washed twice with 4 ml of HEPES buffer at 4°C. Radioactivity was measured in a liquid scintillation counter (Filter Count; Packard).


**Isolated HLP Strip Preparation.** Strips of HLP (1.5–2 cm) were prepared from macroscopically normal human lung specimens placed in cold (4°C) saline solution and studied within 120 min from resection. The HLP strips were suspended in 5-ml organ baths con-

taining Tyrode's solution (composed of 140 mM NaCl, 3 mM KCl, 1 mM  $\text{CaCl}_2$ , 0.05 mM  $\text{MgCl}_2$ , 0.5 mM  $\text{NaH}_2\text{PO}_4$ , 8.4 mM glucose, and 12 mM  $\text{NaHCO}_3$ ), maintained at 37°C, and bubbled with 95%  $\text{O}_2$ , 5%  $\text{CO}_2$ , pH 7.4. Contractions were measured with a Basile 7004 isometric force transducer and recorded on a Basile Gemini 7070 polygraph. HLP strips were set at an initial tension of 1 g, washed with fresh buffer every 15 min over a 60-min equilibration period, and then treated with 40 mM serine-borate complex and 3 mM L-cysteine to inhibit  $\text{LTC}_4$  and  $\text{LTD}_4$  metabolism. For antagonist studies, after 15 min, cumulative concentration-response curves were obtained with an increasing concentration of  $\text{LTC}_4$  or  $\text{LTD}_4$  (0.1 nM to 1  $\mu\text{M}$ ). At 15 min later, either a concentration of 10  $\mu\text{M}$  of each antagonist tested or the vehicle DMSO was added. Only one  $\text{LTC}_4$  or  $\text{LTD}_4$  concentration-response curve was obtained from each HLP strip. The contractile response to each concentration of  $\text{LTC}_4$  or  $\text{LTD}_4$  was expressed as percent of the maximal response to 300  $\mu\text{M}$   $\text{PGF}_{2\alpha}$ .

**Computer Analysis.** Analysis of binding data of association and homologous dissociation time-courses was performed using the program KINFIT II (Rovati et al., 1996). The computerized analysis of the data through KINFIT II has several advantages, as it allows 1) simultaneously analysis of association and dissociation time courses;



**Fig. 2.** Effect of (S)-decyl-GSH on the ability of agonist and antagonist to dissociate  $^3\text{H-LTC}_4$  and  $^3\text{H-LTD}_4$  binding at equilibrium. A, effect of 10  $\mu\text{M}$  (S)-decyl-GSH on displacement of 1  $\mu\text{M}$   $\text{LTC}_4$  and 10  $\mu\text{M}$  concentration of the indicated antagonists versus  $^3\text{H-LTC}_4$ . B, effect of 10  $\mu\text{M}$  (S)-decyl-GSH on displacement of 1  $\mu\text{M}$   $\text{LTD}_4$  and 10  $\mu\text{M}$  concentration of the indicated antagonists versus  $^3\text{H-LTD}_4$ . Data are expressed as mean  $\pm$  S.E. of three replicates from at least three experiments.



**Fig. 3.** Effect of (S)-decyl-GSH on  $^3\text{H-LTC}_4$  and antagonist binding in kinetic studies. A, dissociation time courses of  $^3\text{H-LTC}_4$  in the absence (●) and presence (○) of 10  $\mu\text{M}$  (S)-decyl-GSH. Inset, parameters C (amount bound, nM) and  $k_{\text{off}}$  ( $\text{s}^{-1}$ ) of the curves shown. B, heterologous dissociation time courses for 10  $\mu\text{M}$  pranlukast versus  $^3\text{H-LTC}_4$  in the absence (◆) and presence (◇) of 10  $\mu\text{M}$  (S)-decyl-GSH. Inset, parameters C (percent specific binding) and  $k_{\text{off}}$  ( $\text{s}^{-1}$ ) of the curves shown. Data are mean values of two replicates from a single experiment, representative of at least two other experiments.

2) calculation of  $k_{on}$ ,  $k_{off}$ , and  $B_{max}$  directly in the same analysis without any further approximation; 3) performance of association time courses using a mixture of labeled and unlabeled ligands; and 4) selective labeling of a high-affinity/low-capacity class of sites using a low-specific-activity compound. Binding is expressed as specific bound concentration versus time.

Data from heterologous dissociation time courses were analyzed using EXPFIT (Guardabasso et al., 1988), which calculates the coefficients  $C$  (amount or percent bound) and  $R$  (the apparent rate constant for the specified antagonist). No direct calculation of  $k_{off}$  was possible for the heterologous dissociation time courses. Biphasic dissociation time courses represent interaction with a heterologous population of sites, where the fast dissociation rate represents the low-affinity component and the low dissociation rate represents the high-affinity component. Antagonist competition is expressed as percent dissociation specific binding.

Statistical analysis of concentration-response curves was performed by using the computer program ALLFIT (De Lean et al., 1978), which calculates the lower and upper plateaus, the slope, and the  $EC_{50}$  value.

Different models of increasing complexity were selected using the statistical principle of the "extra sum of squares" (Draper and Smith, 1966). Parameter errors are always expressed in percent coefficient of variation (% CV). A statistical level of significance of  $P < .05$  was accepted. All of the curves shown were computer generated.

## Results


**Effect of (S)-Decyl-GSH on <sup>3</sup>H-LTC<sub>4</sub> and <sup>3</sup>H-LTD<sub>4</sub> Binding.** The ability of a series of antagonists (10  $\mu$ M) to compete for <sup>3</sup>H-LTC<sub>4</sub> binding was assessed at equilibrium (Fig. 2A). In the presence of (S)-decyl-GSH, only pobilukast retained the ability to displace <sup>3</sup>H-LTC<sub>4</sub> from its binding sites, whereas no appreciable effect was observed for agonist binding. The same experiment was repeated using <sup>3</sup>H-LTD<sub>4</sub> in the absence and presence of 10  $\mu$ M (S)-decyl-GSH. In the absence of (S)-decyl-GSH, all of the antagonists tested were

able to inhibit <sup>3</sup>H-LTD<sub>4</sub> binding, whereas in the presence of (S)-decyl-GSH, the profile of antagonism was identical to that obtained versus <sup>3</sup>H-LTC<sub>4</sub> (Fig. 2B).

In Fig. 3 we tested the ability of (S)-decyl-GSH to interfere with <sup>3</sup>H-LTC<sub>4</sub> binding in kinetic studies. Dissociation time courses are biphasic ( $P < .05$ ), representing interaction with a heterologous population of sites, where the fast dissociation rate represents the low-affinity component and the low dissociation rate represents the high-affinity component. (S)-Decyl-GSH did not affect the kinetic parameters but abolished 75% of <sup>3</sup>H-LTC<sub>4</sub> specific binding [ratio of the specific binding,  $C_1 + C_2$ , in the absence and presence of (S)-decyl-GSH; Fig. 3A]. Furthermore, (S)-decyl-GSH prevented pranlukast-induced dissociation of <sup>3</sup>H-LTC<sub>4</sub> from its high-affinity binding site (Fig. 3B). On the basis of these results, all of the subsequent experiments were performed using a kinetic protocol in the absence of (S)-decyl-GSH.

**<sup>3</sup>H-LTD<sub>4</sub> and <sup>3</sup>H-LTC<sub>4</sub> Time Courses.** <sup>3</sup>H-LTD<sub>4</sub> and <sup>3</sup>H-LTC<sub>4</sub> association time courses were performed at different concentrations of total ligand (see *Experimental Procedures*): 0.5 nM to prevalently label the high-affinity sites (Figs. 4 and 5, respectively, and Table 1) and 0.1  $\mu$ M to also label the low-affinity sites (Table 1). Both dissociation curves are biphasic. Simultaneous computerized analysis of association and dissociation time courses performed at different total ligand concentrations confirmed the presence of two classes of binding sites for both LTC<sub>4</sub> and LTD<sub>4</sub> ( $P < .05$ ). Parameters are reported in Table 1.

Shown are <sup>3</sup>H-LTD<sub>4</sub> and <sup>3</sup>H-LTC<sub>4</sub> (Figs. 4 and 5, insets, respectively) dissociation time courses performed in the absence and presence of 30  $\mu$ M Gpp(NH)p, a nonhydrolyzable GTP analog. Gpp(NH)p was able to almost completely shift the high-affinity <sup>3</sup>H-LTD<sub>4</sub> binding to its low-affinity component [from 38 to 89% low-affinity site in the absence and



**Fig. 4.** Association and dissociation time courses for <sup>3</sup>H-LTD<sub>4</sub>. ●, 0.5 nM <sup>3</sup>H-LTD<sub>4</sub> in the association phase; dissociation was induced by 1  $\mu$ M LTD<sub>4</sub>. ○, 10 nM total LTD<sub>4</sub> (2 nM <sup>3</sup>H-LTD<sub>4</sub> plus 8 nM LTD<sub>4</sub>) in the association phase; dissociation was induced by 1  $\mu$ M LTD<sub>4</sub>. Inset, 0.5 nM <sup>3</sup>H-LTD<sub>4</sub> in the association phase (data not shown); dissociation was induced by 1  $\mu$ M LTD<sub>4</sub> in the absence (●) and in the presence (△) of 30  $\mu$ M Gpp(NH)p. Data are mean values of three replicates from a single experiment, representative of at least two other experiments.



presence of Gpp(NH)p, respectively]. On the contrary, Gpp(NH)p had no effect on the high-affinity site labeled by  $^3\text{H-LTC}_4$ .

**Antagonist Binding Studies.** Heterologous dissociation time courses were performed with a series of "classic" CysLT<sub>1</sub> antagonists (Brooks and Summers, 1996) and the dual antagonist BAY u9773 (Cuthbert et al., 1991).

All of the antagonists tested (Table 2) were able to dissociate  $^3\text{H-LTD}_4$  from its binding sites. Figure 6A shows the curves for three of these antagonists (the others are not shown for the sake of clarity) in comparison with the homologous curve. All antagonist-induced  $^3\text{H-LTD}_4$  dissociation curves were biphasic ( $P < .05$ ). On the contrary, only pobikukast, pranlukast, and CGP 57698 dissociated  $^3\text{H-LTC}_4$  from its high-affinity binding sites, whereas zafirlukast, iralukast, and BAY u9773 did not (Fig. 6B and Table 2). Again, only three curves are shown for the sake of clarity.


The apparent potencies of the different antagonists in displacing  $^3\text{H-LTC}_4$  and  $^3\text{H-LTD}_4$  are presented in Table 2 as percent dissociation at 60 min.

**Isometric Contraction of Isolated HLP Strips.** Figure 7 shows LTD<sub>4</sub> and LTC<sub>4</sub> cumulative concentration-response curves obtained from isometric contractions of HLP strips. The EC<sub>50</sub> values are  $6.6 \text{ nM} \pm 46\% \text{ CV}$  and  $91 \text{ nM} \pm 3.3\% \text{ CV}$ , and the maximal contractions (expressed as percent versus PGF<sub>2 $\alpha$</sub> ) are  $190 \pm 9.5\% \text{ CV}$  and  $111 \pm 3.5\% \text{ CV}$  for LTD<sub>4</sub> and LTC<sub>4</sub>, respectively.

All of the antagonists were tested up to a concentration of 10  $\mu\text{M}$  and were able to completely reverse (>85%) both LTD<sub>4</sub>- and LTC<sub>4</sub>-induced contractions, with the only exception of BAY u9773. The dual antagonist was less active than the other compounds with a maximal inhibition lower than 50% (data not shown), and BAY u9773 presented a partial agonist activity in most of the experiments. Tracings from a typical experiment for pranlukast and iralukast versus LTC<sub>4</sub> are shown in Fig. 8, A and B, respectively.

### Discussion

It is well known that LTC<sub>4</sub> predominantly binds to a number of nonreceptor sites in cellular membranes (Keppler,



**Fig. 5.** Association and dissociation time courses for  $^3\text{H-LTC}_4$ . ■, 0.5 nM  $^3\text{H-LTC}_4$  in the association phase; dissociation was induced by 1  $\mu\text{M}$  LTC<sub>4</sub>. Inset, 0.5 nM  $^3\text{H-LTC}_4$  in the association phase (data not shown); dissociation was induced by 1  $\mu\text{M}$  LTC<sub>4</sub> in the absence (■) and in the presence (□) of 30  $\mu\text{M}$  Gpp(NH)p. Data are mean values of three replicates from a single experiment, representative of at least two other experiments.

**TABLE 1**  
Kinetic parameters for  $^3\text{H-LTD}_4$  and  $^3\text{H-LTC}_4$   
 $k_{\text{on}}$  values are expressed in  $\text{M}^{-1} \cdot \text{s}^{-1}$ ,  $k_{\text{off}}$  values are expressed as  $\text{s}^{-1}$ .  $K_d$  values are the ratio of  $k_{\text{off}}$  to  $k_{\text{on}}$  and are expressed in nM.  $B_{\text{max}}$  values are expressed as pmol/mg protein. Parameters are expressed as mean  $\pm$  % CV.

$^3\text{H-LTD}_4$			$^3\text{H-LTC}_4$		
$k_{\text{on1}}$	$2.7 \times 10^6 \pm 28$	$K_{d1}$	$1.5 \times 10^7 \pm 96$	$K_{d1}$	0.053
$k_{\text{off1}}$	$1.7 \times 10^{-4} \pm 39$		$7.8 \times 10^{-4} \pm 33$		
$B_{\text{max1}}$	$0.0073 \pm 17$	$K_{d2}$	$0.0095 \pm 42$	$K_{d2}$	83
$k_{\text{on2}}$	$1.8 \times 10^5 \pm 85$		$3.3 \times 10^5 \pm 51$		
$k_{\text{off2}}$	$4 \times 10^{-3} \pm 45$		$2.7 \times 10^{-2} \pm 35$		
$B_{\text{max2}}$	$0.074 \pm 87$		$5.5 \pm 26$		

1992; Metters et al., 1994). As we previously demonstrated (Capra et al., 1998), to unmask a specific high-affinity binding site for LTC<sub>4</sub>, (S)-decyl-GSH must be routinely included in the <sup>3</sup>H-LTC<sub>4</sub> binding assay at equilibrium to inhibit the



TABLE 2

Antagonist-induced dissociation at 60 min

Parameters are expressed as mean ± % CV.


	<sup>3</sup> H-LTD <sub>4</sub>	<sup>3</sup> H-LTC <sub>4</sub>
	% dissociation at 60 min	
Pobilukast	47 ± 42	53 ± 12
Pranlukast	75 ± 10	38 ± 47
CGP 57698	69 ± 31	46 ± 21
Zafirlukast	62 ± 3	N.D.
Iralukast	52 ± 8	N.D.
BAY u9773	47 ± 12	N.D.

N.D., not detectable.




**Fig. 6.** Homologous and heterologous dissociation time courses. A, labeled ligand 0.5 nM <sup>3</sup>H-LTD<sub>4</sub>; dissociation was induced by 1 μM LTD<sub>4</sub> (●), 10 μM pobilukast (▲), zafirlukast (◇), and BAY u9773 (□). B, labeled ligand 0.5 nM <sup>3</sup>H-LTC<sub>4</sub>; dissociation was induced by 1 μM LTC<sub>4</sub> (■), 10 μM pobilukast (▲), zafirlukast (◇), and BAY u9773 (□). Data are mean values of three replicates from a single experiment, representative of at least two other experiments. S.E. values are not shown for the sake of clarity.

interaction with most of these lower-affinity nonreceptor sites. However, we observed that all of the antagonists tested, with the exception of pobilukast, were unable to compete for <sup>3</sup>H-LTC<sub>4</sub> binding in the presence of (S)-decyl-GSH. To elucidate whether (S)-decyl-GSH might interfere with the antagonist binding, we selected one representative compound from each structural class of antagonists and tested them in HLP membranes, also against <sup>3</sup>H-LTD<sub>4</sub> in the absence and presence of (S)-decyl-GSH. Surprisingly, in the presence of (S)-decyl-GSH, the antagonists were unable to also compete for <sup>3</sup>H-LTD<sub>4</sub>, indicating that this compound interferes with antagonist but not with agonist binding (Fig. 2). Interestingly, only the binding of pobilukast, the antago-



**Fig. 7.** Cumulative concentration-response curves of LTD<sub>4</sub> (●) and LTC<sub>4</sub> (■) induced contraction of isolated HLP strips. Data are mean values of four to six replicates ± S.E.



**Fig. 8.** Effect of pranlukast (A) and iralukast (B) on cumulative concentration-response curve of LTC<sub>4</sub> in isolated HLP strips. Data are from a single experiment, representative of at least two other experiments.

nist with the structure closest to that of cysteinyl-LTs, was not affected by (S)-decyl-GSH.

Because the presence of (S)-decyl-GSH prevents the pharmacological characterization of  $^3\text{H-LTC}_4$  binding at equilibrium, to avoid the use of (S)-decyl-GSH, we have performed the pharmacological characterization of the  $^3\text{H-LTC}_4$  high-affinity site by means of kinetic binding studies. This protocol is rarely used for this purpose, yet in this specific case, with  $K_{d1}$  far apart from  $K_{d2}$  (1600-fold difference), it is possible to choose a concentration of  $^3\text{H-LTC}_4$  to saturate the high-affinity/low-capacity site without saturating the low-affinity/high-capacity site in the association phase (Rovati et al., 1996; Rovati, 1998). Clearly, a portion of the low-affinity sites, due to their abundance, is also labeled (dissociation time courses are always biphasic). However, with this approach, there is no longer a need to inhibit the binding to the lower-affinity sites by means of (S)-decyl-GSH. The same also applies, in part, to  $^3\text{H-LTD}_4$ , despite the difference between  $K_{d1}$  and  $K_{d2}$  being only 340-fold.

Thus, having primarily labeled the high-affinity binding sites, one can perturb the equilibrium with the antagonists to assess their ability to dissociate  $^3\text{H-LTD}_4$  and  $^3\text{H-LTC}_4$  from both sites. This protocol is indeed a heterologous dissociation time course, which allows a study of the interaction of unlabeled ligands (i.e., the antagonists) with  $^3\text{H-LTD}_4$  and  $^3\text{H-LTC}_4$ . The only limitation of this type of protocol is that no dissociation constants for the antagonist can be calculated, but only their apparent potency order (Table 2).

We observed that (S)-decyl-GSH interferes with antagonist-induced  $^3\text{H-LTC}_4$  dissociation from its high-affinity sites without interfering with the kinetic parameters of the agonist (Fig. 3), confirming the data obtained at equilibrium. A possible explanation for these findings could reside in a non-total coincidence of agonist and antagonist sites on CysLT receptors and in the steric hindrance of (S)-decyl-GSH at the antagonist binding site.

The results obtained from the simultaneous computerized analysis of association and dissociation time courses for  $^3\text{H-LTD}_4$  and  $^3\text{H-LTC}_4$  confirmed the model and parameters (Table 1) for cysteinyl-LT binding sites in HLP (Capra et al., 1998), thus validating the kinetic approach in the absence of (S)-decyl-GSH. In fact,  $\text{LTD}_4$  interacts with two interconvertible states of a G protein-coupled receptor, whereas  $\text{LTC}_4$  displays a different kinetic profile, and both sites are GTP insensitive.

Heterologous dissociation time courses indicated that among all of the "classic" CysLT<sub>1</sub> antagonists we tested, only pobilukast, pranlukast, and CGP 57698 were able to dissociate both  $^3\text{H-LTD}_4$  and  $^3\text{H-LTC}_4$  from their high- and low-affinity binding sites. On the contrary, zafirlukast and iralukast were unable to interact with the  $^3\text{H-LTC}_4$  high-affinity binding site (Fig. 6 and Table 2), whereas they retain the ability to dissociate the ligand from the nonreceptor sites (low-affinity component). Hence,  $^3\text{H-LTC}_4$  high-affinity binding site has a unique pharmacological profile, suggesting the existence of a specific  $\text{LTC}_4$  receptor different from that of  $\text{LTD}_4$  (CysLT<sub>1</sub>).

Among all of the cysteinyl-LT antagonists available, BAY u9773 is, until now, the only compound able to recognize both CysLT<sub>1</sub> and CysLT<sub>2</sub> receptors (Coleman et al., 1995). In HLP membranes, BAY u9773 is indeed able to dissociate  $^3\text{H-LTD}_4$  from both of its sites but is unable to dissociate  $^3\text{H-LTC}_4$  from

its high-affinity sites, thus excluding that this  $\text{LTC}_4$  specific site is a CysLT<sub>2</sub> receptor.

Taken together, these binding data confirm our hypothesis that HLP membranes contain two cysteinyl-LT high-affinity binding sites with different kinetic (sensitivity to GTP) and pharmacological profiles.  $\text{LTD}_4$  binding sites can be classified as a CysLT<sub>1</sub> receptor (Lynch et al., 1999), whereas  $\text{LTC}_4$  high-affinity binding site is neither a CysLT<sub>1</sub> nor a CysLT<sub>2</sub> receptor. Moreover, these results indicate that classic antagonists should no longer be considered a homogeneous class of compounds with respect to  $\text{LTC}_4$  binding sites and that their specificity seems to be unrelated to the chemical structure, because antagonists of the same class (e.g., pobilukast, iralukast, and BAY u997) behave differently versus the two different receptors.

It is well known that in human airways, CysLT<sub>1</sub> receptors predominantly mediate the contraction of smooth muscle tissue, thus playing an important role in the acute phase of asthma. To evaluate whether  $\text{LTD}_4$  and  $\text{LTC}_4$  share the same effect and the same pharmacological profile in isolated HLP strips, all of the antagonists were also tested in a functional assay against  $\text{LTD}_4$ - and  $\text{LTC}_4$ -induced contractions. Despite the fact that  $\text{LTD}_4$  and  $\text{LTC}_4$  have different potencies (14-fold difference) and efficacies (1.7-fold difference; Fig. 7), all of the classic antagonists tested were able to reverse  $\text{LTD}_4$ - as well as  $\text{LTC}_4$ -induced contractions up to 85 to 100%. BAY u9773 showed a lower efficacy (60% inhibition of  $\text{LTD}_4$ - and  $\text{LTC}_4$ -induced contractions at the same time point), suggesting it could behave as a partial agonist, as already proposed both in this tissue (Wikstrom Jonsson et al., 1998) and in human pulmonary veins (Gardiner et al., 1994).

Thus, we can conclude that  $\text{LTD}_4$  and  $\text{LTC}_4$  contract isolated HLP strips through the same CysLT<sub>1</sub> receptor, as already suggested by Gardiner and Cuthbert (1988) on the basis of more limited data (only one antagonist, FPL 55712). The specific and characteristic  $\text{LTC}_4$  high-affinity binding site cannot be classified among one of the officially recognized CysLT receptors, nor it is implicated in  $\text{LTC}_4$ -induced HLP strip contractions. The recent cloning of the CysLT<sub>1</sub> receptor (Lynch et al., 1999) will rapidly lead to the identification and characterization of the different classes and subclasses of CysLT receptors, but the  $\text{LTC}_4$  specific binding site identified here is unlikely to be one of these. In fact, this binding site is not GTP sensitive (Fig. 5 and Capra et al., 1998) and thus should not belong to the superfamily of seven-transmembrane domain receptors.

It is tempting to speculate that this putative receptor is implicated in aspects of the asthmatic syndrome different from bronchoconstriction, such as smooth muscle hyperplasia and proliferation or mucus secretion. Indeed, there are data in the literature that indicate a proliferative role of cysteinyl-LTs in human airway epithelial (Leikauf et al., 1990) or smooth muscle (Panettieri et al., 1998) cells. These data not only suggest  $\text{LTC}_4$  as a more potent mitogenic stimulus than  $\text{LTD}_4$  (Leikauf et al., 1990) but also indicate  $\text{LTD}_4$  to be a weak agonist with a different pharmacological profile compared with the classic contractile function mediated by the CysLT<sub>1</sub> receptor.

Although direct evidence to correlate proliferation with the putative  $\text{LTC}_4$  receptor is still lacking, our findings might prompt a deeper investigation into the role of  $\text{LTC}_4$ , not only as a precursor of  $\text{LTD}_4$ /LTE<sub>4</sub> but also as an active indepen-

dent agonist per se. This in turn might contribute to the discovery and development of new and more active drugs with a wider spectrum of action to be used in the treatment of an overlooked disease such as asthma.

Finally, our data also suggest that the homologous kinetic protocol is a valid alternative to classic equilibrium binding studies when supported by sophisticated data analysis. The intrinsic complexity of these experiments can be easily offset by the advantages that this type of protocol presents in particular biological systems where equilibrium studies might fail for theoretical or practical reasons (e.g., when one deals with a high-affinity ligand with a low specific activity; Rovati, 1998). Moreover, heterologous dissociation time courses, albeit with the limitation previously discussed, appear to be a powerful tool for the study of the kinetic characteristics of compounds not available in the labeled form.

#### Acknowledgments

We acknowledge Dr. A. von Sprecher (Research Department, Pharmaceutical Division, Novartis Ltd., Basel, Switzerland) for providing LTD<sub>4</sub> and the antagonists. We give special thanks to Dr. M. R. Accomazzo for her skillful assistance in HPLC analysis of labeled and unlabeled leukotrienes and in isolated HLP strip preparation.

#### References

- Brooks CDW and Summers JB (1996) Modulators of leukotriene biosynthesis and receptor activation. *J Med Chem* **39**:2629–2654.
- Buckner CK, Fedyna JS, Robertson JL, Will JA, England DM, Krell RD and Saban R (1990) An examination of the influence of the epithelium on contractile responses to peptidoleukotrienes and blockade by ICI 204,219 in isolated guinea pig trachea and human intralobar airways. *J Pharmacol Exp Ther* **252**:77–85.
- Buckner CK, Krell RD, Laravuso RB, Coursin DB, Bernstein PR and Will JA (1986) Pharmacological evidence that human intralobar airways do not contain different receptor that mediate contractions to leukotriene C<sub>4</sub> and leukotriene D<sub>4</sub>. *J Pharmacol Exp Ther* **237**:558–562.
- Capra V, Nicosia S, Ragnini D, Mezzetti M, Keppler D and Rovati GE (1998) Identification and characterization of two Cys-leukotriene high-affinity binding sites with receptor characteristics in human lung parenchyma. *Mol Pharmacol* **53**:750–758.
- Coleman RA, Eglen RM, Jones RL, Narumiya S, Shimizu T, Smith WL, Dahlén SE, Drazen JM, Gardiner PJ, Jackson WT, Jones TR, Krell RD and Nicosia S (1995) Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature, in *Advances in Prostaglandin, Thromboxane, and Leukotriene Research* (Samuelsson B, Ramwell PW, Paoletti R, Folco G, Granström E and Nicosia S eds) pp 283–285, Raven Press, New York.
- Cuthbert NJ, Tudhope SR, Gardiner PJ, Abram TS, Norman P, Thompson AM, Maxey RJ and Jennings MA (1991) BAY u9773, an LTC<sub>4</sub> antagonist in the guinea pig trachea. *Ann NY Acad Sci* **629**:402–404.
- De Lean A, Munson PJ and Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves. *Am J Physiol* **235**:E97–E102.
- Draper NR and Smith H (1966) *Applied Regression Analysis*. Wiley, New York.
- Drazen JM and Austen KF (1987) Leukotrienes and airway responses. *Am Rev Respir Dis* **135**:333–337.
- Gardiner PJ, Abram TS, Tudhope SR, Cuthbert NJ, Norman P and Brink C (1994) Leukotriene receptors and their selective antagonists, in *Advances in Prostaglandin, Thromboxane, and Leukotriene Research* (Dahlén S eds) pp 49–61, Raven Press, New York.
- Gardiner PJ and Cuthbert NJ (1988) Characterisation of the leukotriene receptor(s) on human isolated lung strips. *Agents Actions Suppl* **23**:121–128.
- Guardabasso V, Munson PJ and Rodbard D (1988) EXPFIT: A program for simultaneous analysis of families of exponential decay curves. *Comput Methods Progr Biomed* **27**:55–63.
- Hay D, Torphy TJ and Undem BJ (1995) Cysteinyl leukotrienes in asthma: Old mediators up to new tricks. *Trends Pharmacol Sci* **16**:304–309.
- Hay DW, Muccitelli RM, Tucker SS, Vickery-Clark LM, Wilson KA, Gleason JG, Hall RF, Wasserman MA and Torphy TJ (1987) Pharmacologic profile of SK&F 104353: A novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. *J Pharmacol Exp Ther* **243**:474–81.
- Keppler D (1992) Leukotrienes: Biosynthesis, transport, inactivation, and analysis. *Rev Physiol Biochem Pharmacol* **121**:1–30.
- Labat C, Ortiz JL, Norel X, Gorenne I, Verley J, Abram TS, Cuthbert NJ, Tudhope SR, Norman P, Gardiner P and Brink C (1992) A second cysteinyl leukotriene receptor in human lung. *J Pharmacol Exp Ther* **263**:800–805.
- Leikauf GD, Claesson HE, Doupnik CA, Hybbinette S and Grafstrom RC (1990) Cysteinyl leukotrienes enhance growth of human airway epithelial cells. *Am J Physiol* **259**:L255–L261.
- Lynch KR, Gary P, O'Neill GP, Qingyun Liu Q, Im D-S, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, Connolly BM, Bai C, Austin CP, Chateaufneuf A, Stocco R, Greig GM, Kargman S, Hooks SB, Hosfield E, Williams Jr DL, Ford-Hutchinson AW, Caskey CT and Evans JF (1999) Characterization of the human cysteinyl leukotriene CysLT<sub>1</sub> receptor. *Nature (Lond)* **399**:789–793.
- Metters KM, Sawyer N and Nicholson DW (1994) Microsomal glutathione S-transferase is the predominant leukotriene C<sub>4</sub> binding site in cellular membranes. *J Biol Chem* **269**:12816–12823.
- Panettieri RA, Tan EM, Ciocca V, Luttmann MA, Leonard TB and Hay DW (1998) Effects of LTD<sub>4</sub> on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: Differential sensitivity to cysteinyl leukotriene receptor antagonists. *Am J Respir Cell Mol Biol* **19**:453–61.
- Rovati GE (1998) Ligand-binding studies: Old belief and new strategies. *Trends Pharmacol Sci* **19**:365–369.
- Rovati GE, Oliva D, Sautebin L, Folco GC, Welton AF and Nicosia S (1985) Identification of specific binding sites for leukotriene C<sub>4</sub> in membranes from human lung. *Biochem Pharmacol* **34**:2831–2837.
- Rovati GE, Shrager R, Nicosia S and Munson PJ (1996) KINFIT II: A nonlinear least squares program for analysis of kinetic binding data. *Mol Pharmacol* **50**:86–95.
- Saussy DL Jr, Sarau HM, Foley JJ, Mong S and Crooke ST (1989) Mechanisms of leukotriene E<sub>4</sub> partial agonist activity at leukotriene D<sub>4</sub> receptors in differentiated U-937 cells. *J Biol Chem* **264**:19845–55.
- Wikstrom Jonsson E, Rosenqvist U and Dahlen SE (1998) Agonist and antagonist activities of the leukotriene analogue BAY u9773 in guinea pig lung parenchyma. *Eur J Pharmacol* **357**:203–11.

**Send reprint requests to:** Dr. G. Enrico Rovati, Institute of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy. E-mail: GEnrico.Rovati@unimi.it